AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Spinocerebellar Ataxia (SCA) Pipeline Review, H2 2020 - Therapeutics Development and Assessment, Drug Profiles, Dormant Projects, Product Development Milestones, Competitive Landscape - ResearchAndMarkets.com

January 12, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jan 12, 2021--

The “Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

ADVERTISEMENT

Spinocerebellar Ataxia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinocerebellar Ataxia (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Spinocerebellar Ataxia (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinocerebellar Ataxia (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders)

ADVERTISEMENT

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Spinocerebellar Ataxia - Overview

Spinocerebellar Ataxia - Therapeutics Development

Spinocerebellar Ataxia - Therapeutics Assessment

Spinocerebellar Ataxia - Companies Involved in Therapeutics Development

Spinocerebellar Ataxia - Drug Profiles

Spinocerebellar Ataxia - Dormant Projects

Spinocerebellar Ataxia - Discontinued Products

Spinocerebellar Ataxia - Product Development Milestones

Appendix

Companies Mentioned

  • Allianz Pharmascience Ltd
  • Anima Biotech Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioXcel Corp
  • Celavie Biosciences LLC
  • Dystrogen Therapeutics SA
  • Enzerna Biosciences LLC
  • Everfront Biotech Inc
  • Exicure Inc
  • Gene Therapy Research Institution Co Ltd
  • IntraBio Ltd
  • Ionis Pharmaceuticals Inc
  • Lacerta Therapeutics Inc
  • Sclnow Biotechnology Co Ltd
  • Seelos Therapeutics, Inc.
  • Shionogi & Co Ltd
  • Spark Therapeutics Inc
  • Steminent Biotherapeutics Inc
  • Triplet Therapeutics Inc
  • UniQure NV
  • Vico Therapeutics BV
  • Vybion Inc
  • Wave Life Sciences Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nn728y

View source version on businesswire.com:https://www.businesswire.com/news/home/20210112005795/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: GENETICS PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 01/12/2021 11:05 AM/DISC: 01/12/2021 11:06 AM

http://www.businesswire.com/news/home/20210112005795/en